Response Biomedical Inks C$2M Debt Financing Pact | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Biomedical today announced that it has entered into a C$2 million (US$1.9 million) debt financing agreement with Orbimed Advisors.

The Vancouver, British Columbia-based firm has structured the debt agreement so it can borrow money in tranches. Upon execution of the pact, it will draw down C$275,000 from Orbimed. It also has an option to draw down up to three further tranches of C$575,000, for a maximum potential draw of C$2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.